Mariusz Pytkowski Selected Research

Antazoline (Antazoline Phosphate)

1/2022	Rapid pharmacological cardioversion of recent-onset atrial fibrillation using antazoline in elderly patients.
1/2019	Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).
12/2018	Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
10/2017	Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the AnPAF Study).
9/2012	Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mariusz Pytkowski Research Topics

Disease

11	Atrial Fibrillation 01/2022 - 10/2002
6	Heart Failure 12/2018 - 04/2004
4	Cardiac Arrhythmias (Arrythmia) 01/2020 - 04/2012
4	Ventricular Tachycardia 01/2020 - 12/2003
4	Cardiac Sudden Death (Sudden Cardiac Arrest) 09/2010 - 10/2005
3	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 12/2019 - 10/2005
3	Ventricular Fibrillation 01/2017 - 03/2006
2	Thrombosis (Thrombus) 10/2021 - 10/2005
2	Ventricular Premature Complexes (Premature Ventricular Contraction) 01/2021 - 01/2013
2	Coronary Artery Disease (Coronary Atherosclerosis) 12/2018 - 09/2014
2	Reciprocating Tachycardia 11/2016 - 12/2014
2	Supraventricular Tachycardia 12/2014 - 09/2010
2	Myocardial Infarction 01/2012 - 03/2006
1	Infections 01/2020
1	Atrial Flutter (Flutter, Atrial) 01/2020
1	Systolic Heart Failure 12/2018
1	Tachycardia (Tachyarrhythmias) 10/2017
1	Pulmonary Embolism 01/2016
1	Endocarditis 07/2014
1	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2013
1	Cardiomyopathies (Cardiomyopathy) 04/2012
1	Hemorrhage 10/2002

Drug/Important Bio-Agent (IBA)

5	Antazoline (Antazoline Phosphate)FDA Link 01/2022 - 09/2012
2	Amiodarone (Amiodarona)FDA LinkGeneric 12/2018 - 01/2017
2	vernakalantIBA 12/2018 - 09/2012
1	Adenosine (Adenocard)FDA LinkGeneric 04/2021
1	Pharmaceutical PreparationsIBA 01/2019
1	Mexiletine (Mexitil)FDA LinkGeneric 01/2017
1	ORALIT (ORS)IBA 09/2015
1	Adenosine Triphosphate (ATP)IBA 09/2014
1	Anti-Arrhythmia AgentsIBA 09/2012
1	butaneIBA 03/2006
1	Heparin (Liquaemin)FDA LinkGeneric 10/2005

Therapy/Procedure

10	Therapeutics 10/2021 - 10/2002
9	Electric Countershock (Cardioversion) 01/2022 - 10/2002
8	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 12/2019 - 10/2005
6	Radiofrequency Ablation 01/2020 - 09/2010
5	Catheter Ablation 01/2020 - 12/2003
3	Defibrillators (Defibrillator) 03/2006 - 10/2002
2	Catheters 01/2021 - 01/2020
2	Cardiac Resynchronization Therapy 12/2018 - 10/2014
1	Contraindications 01/2016
1	Cardiac Resynchronization Therapy Devices 10/2014
1	Secondary Prevention 09/2010